Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan

Lung Cancer

Volumn 35, Issue 3, 2002, Pages 299-304

  Tsurutani, Junji ^a,d   Nitta, Takashi ^b   Hirashima, Tomonori ^b   Komiya, Takefumi ^a   Uejima, Hisao ^a   Tada, Hirohito ^c   Syunichi, Negoro ^c   Tohda, Aritomo ^a   Fukuoka, Masahiro ^a   Nakagawa, Kazuhiko ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

Author keywords

Drug resistance; Irinotecan; Mutation; Topoisomerase I

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE; IRINOTECAN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TREATMENT OUTCOME;

EID: 0036178991     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00425-1     Document Type: Article

References (22)

1. Irinotekan in small-cell lung cancer-Japanese trials
2. A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer
3. Irinotecan plus fluorouracil and leucovorin for metasitatic colorectal cancer
4. Mutation at the catalytic site of topoisomerase I CEM/C2, a human leukemia cell line resistant to camptothecin
5. Identification of a mutant topoisomerase I with intact catalatic activity and resistance to 9-nitrocamptothecin
6. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I cystine
7. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites
8. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line
9. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line
10. Gene mutation analysis and quantitation of DNA topoisomerase I in previously united non-small cell lung carcinomas
11. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer
12. Induction chemotherapy for stage IIA bulky N2 non-small cell lung cancer (NSCLC) with CPT-11 and CDDP
13. Keynote address on biostatistics and data retrieval
14. Single-step method of RNA isolation by acid ganidium thiocynate-phenol-chloroform extraction
15. Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I DNA confers a dominant form of camptotecin resistance
16. Eukaryotic DNA topoisomerase I
17. Decrease expression of DNA topoisomerase I camtothecin-resistant tumor cell lines as determined by monoclonal antibody
18. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomeraseÖücontent
19. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small-cell lung cancer: Characerization and mechanism of resistance
20. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells
21. Higher expression of topoisomerase I in lung cancer than normal lung tissue: Different expression pattern from topoisomerase I
22. Point muations of the topoisomerase II gene in patients with small cell lung cancer treated with etoposide